120 - What's Hot in Medical Mycology

Friday, October 18, 2024

10:30 AM – 11:45 AM US PT

Location: 502 A

All relevant financial relationships have been mitigated.

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-9999-24-002-L01-P
PACE Credits: Maximum of 1 of PACE contact hours
CE Broker: Maximum of 1 CE broker credit hours

Moderator(s)

Lena Heung, MD, PhD

Assistant Professor
Cedars-Sinai Medical Center
Los Angeles, CA, United States
Dimitrios Kontoyiannis, MD

Professor, Infectious Diseases
Infectious Diseases, Infection Control and Employee Health
The University of Texas MD Anderson Cancer Center
Houston, TX, United States

Faculty(s)

Tom Chiller, MD

Chief, Mycotic Diseases Branch
Centers for Disease Control and Prevention
Atlanta, GA, United States
Roger Brüggemann, PhD, PharmD

Full professor
Radboud university medical center
Dora Edith Corzo-León, MD, PhD (she/her/hers)

Postdoctoral Research Fellow
Medical Research Council Centre for Medical Mycology
Exeter, England, United Kingdom

Disclosure(s):

Lena Heung, MD, PhD: 3M: Stocks/Bonds (Public Company) (Ongoing); Kimberly-Clark: Stocks/Bonds (Public Company) (Ongoing); Procter & Gamble: Stocks/Bonds (Public Company) (Ongoing); Solventum: Stocks/Bonds (Public Company) (Ongoing)

Dimitrios P. Kontoyiannis, MD: No financial relationships to disclose

Tom M. Chiller, MD: No financial relationships to disclose

Roger Brüggemann, PhD, PharmD: F2G Ltd: Advisor/Consultant (Ongoing), Honoraria (Ongoing); Gilead Biosciences: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing), Honoraria (Ongoing); Mundipharma: Advisor/Consultant (Ongoing), Honoraria (Ongoing); Pfizer, Inc.: Advisor/Consultant (Terminated, May 16, 2024), Honoraria (Terminated, May 16, 2024)

Dora Edith Corzo-León, MD, PhD: No financial relationships to disclose

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe the clinical features, epidemiology, and diagnosis of emerging fungal infections;
recognize recent developments to optimize antifungal dosing in individual patients;
identify risk factors for invasive fungal diseases and how they affect patient management.

Presentations:

10:30 AM – 10:55 AM US PT

Emerging Fungal Infections
Speaker: Tom M. Chiller, MD – Centers for Disease Control and Prevention
10:55 AM – 11:20 AM US PT

Precision Medicine in the Treatment of Fungal Infections
Speaker: Roger Brüggemann, PhD, PharmD – Radboud university medical center
11:20 AM – 11:45 AM US PT

Comorbidities and Fungal Disease Beyond Immunosuppression: A Global View
Speaker: Dora Edith Corzo-León, MD, PhD (she/her/hers) – Medical Research Council Centre for Medical Mycology